Business & Industry

The Consumer Welfare Standard is severely limited or defective, preventing it from being an appropriate standard for modern antitrust.

Evidence sharply contradicts PhRMA’s contention that its member companies need unregulated drug prices to generate profits that they then reinvest in drug innovation.

Economist Cristina Caffarra, a leader in competition and antitrust, warns that ever-expanding tech giants raise concerns about the extent of their power.

Thirty Years of Indian Economic Reforms: Assessing the Growth and Development of Kerala

Financial Times columnist and author Rana Foroohar talks about her new book Homecoming: The Path to Prosperity in a Post-Global World

Thirty Years of Indian Economic Reforms: Assessing the Growth and Development of Kerala

How big tech barons crush innovation—and how to fight back

Corporate responsibility needs to evolve if businesses are going to rebuild trust and provide real value for society.

President Biden’s first SOTU Address was a missed opportunity to say what he knows to be true: Stock buybacks manipulate the market and leave most Americans worse off

Former health insurance executive turned whistleblower and investigative journalist Wendell Potter discusses the many ways in which the private health insurance system of the US is not serving anyone well except the insurance companies’ owners

US regulators can step in to ensure drug pricing both supports patient access and drug development

US regulators can step in to ensure drug pricing both supports patient access and drug development

The pandemic and electrification are shaking the foundations of the auto industry

The pandemic and electrification are shaking the foundations of the auto industry

Between a rock and a hard place